


**Product Name** : Ruxolitinib sulfate  
**Cat. No.** : PC-45875  
**CAS No.** : 1092939-16-6  
**Molecular Formula** : C<sub>17</sub>H<sub>20</sub>N<sub>6</sub>O<sub>4</sub>S  
**Molecular Weight** : 404.4435  
**Target** : JAK  
**Solubility** : 10 mM in DMSO



## Biological Activity

Ruxolitinib sulfate (INCB-018424 sulfate, INCB18424 sulfate) potent, selective, orally active **JAK1/JAK2** inhibitor with IC<sub>50</sub> of 3.3/2.8 nM, respectively.

Ruxolitinib displays modest selectivity against Tyk2 (6-fold) and marked selectivity (>130-fold) against JAK3.

Ruxolitinib inhibits IL-6 signaling (IC<sub>50</sub>=281 nM), and proliferation of JAK2V617F(+) Ba/F3 cells (IC<sub>50</sub>=127 nM).

Ruxolitinib suppresses erythroid progenitor colony formation from JAK2V617F(+) polycythemia vera patients (IC<sub>50</sub>=67 nM) in primary cultures.

Ruxolitinib markedly reduces level of inflammatory cytokines, and preferentially eliminates neoplastic cells in a mouse model of JAK2V617F(+) MPN.

## References

Quintás-Cardama A, et al. *Blood*. 2010 Apr 15;115(15):3109-17.

Fridman JS, et al. *J Immunol*. 2010 May 1;184(9):5298-307.

Verstovsek S, et al. *N Engl J Med*. 2010 Sep 16;363(12):1117-27.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com